Pantosec (Pantoprazole Sodium)

Pantoprazole selectively and irreversibly blocks the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells. This inhibition stops the final step of acid secretion, resulting in a sustained increase in gastric pH and allowing damaged mucosa to recover.

The dosage of Pantosec is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. The prescriber will specify the appropriate amount, infusion rate, and treatment duration according to current clinical guidelines.

Safety data for pantoprazole sodium in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Pantosec, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Pantosec is an intravenous formulation of pantoprazole, offering rapid and reliable acid suppression compared with oral proton pump inhibitors. It is particularly useful when oral administration is not feasible or when a swift therapeutic effect is required, such as in hospitalized patients with severe reflux or ulcer complications.

Pantosec must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Pantosec is administered by intravenous injection or infusion under the supervision of a qualified healthcare professional. The medication is typically diluted in a compatible IV fluid and infused over a specified period, as directed by the prescriber and according to institutional protocols.

Serious risks include Clostridioides difficile‑associated colitis, severe allergic reactions such as anaphylaxis, hepatic dysfunction, and electrolyte disturbances like hypomagnesemia. Patients should be monitored for signs of infection, rash, liver enzyme changes, or abnormal serum magnesium levels during therapy.

Pantosec is contraindicated in patients with known hypersensitivity to pantoprazole, other proton pump inhibitors, or any component of the formulation. Caution is also advised for individuals with severe liver disease, and it should be avoided in patients where the risk of drug interactions outweighs the therapeutic benefit.